Medical Cannabis for Autism in the UK: Evidence, Access and What Parents Ask

So what does the evidence actually show, why are cannabinoids being studied, and what should autistic people and their families know?

Can medical cannabis help with autism?

Research into cannabinoids has largely focused on specific symptoms and behaviours experienced by autistic people rather than treating autism itself. 

A 2026 systematic review led by Quezia Vasconcelos and published in Progress in Neuro-Psychopharmacology and Biological Psychiatry identified 12 studies of cannabinoid-based interventions in autistic children and adolescents, including four randomised controlled trials.

Some reported improvements in areas including social communication and disruptive behaviour, while others found no significant differences in sleep or overall symptom severity. The researchers concluded that the evidence remained limited and called for larger, better-designed trials. 

Meanwhile, a 2025 systematic review led by Rachel Riera and published in the Journal of Clinical Pharmacology reached a similar conclusion, finding that the certainty of evidence from randomised trials ranged from low to very low.

Autism is a difference in how the brain develops that affects how people see and experience the world. It is not an illness, and there is no treatment or cure. However, autistic people can experience coexisting conditions which may themselves require treatment.

Speaking to Cannabis Health, consultant psychiatrist and medical cannabis prescriber Dr Niraj Singh, who specialises in neurodevelopmental psychiatry, said: “Autism on its own is not a mental health disorder… [but it] can be associated with a number of other mental health conditions such as anxiety, insomnia, PTSD and OCD. In addition, we know that ADHD and autism often co-occur. So, we treat those conditions rather than autism.”

One of the largest trials to date was a 2021 randomised controlled trial led by Adi Aran and published in Molecular Autism. It involved 150 autistic children and young people aged five to 21 who received either a whole-plant cannabis extract containing CBD and THC at a 20:1 ratio, purified CBD and THC at the same ratio, or a placebo.

Among those receiving the whole-plant extract, 49% were rated as much or very much improved on one measure of disruptive behaviour, compared with 21% receiving placebo. Social responsiveness also improved on one measure.

However, another primary measure of disruptive behaviour found no significant difference between the groups. The researchers described the evidence of efficacy as “mixed and insufficient”. 

A smaller 2021 study  by Serap Bilge and Barış Ekici, published in the Journal of Cannabis Research, reported improvements in some autistic children receiving CBD-enriched cannabis.

Parents of the 33 children reported improvements in areas including behaviour, language and cognition. However, the study had no placebo or control group, meaning it cannot establish that cannabis caused the reported changes.

Key studies at a glance

Study	Year	Design	Participants	What it found
Vasconcelos et al., Progress in Neuro-Psychopharmacology and Biological Psychiatry	2026	Systematic review	12 studies, including four RCTs	Some studies reported improvements in areas including social communication and disruptive behaviour, but overall evidence remained limited.
Riera et al., Journal of Clinical Pharmacology	2025	Systematic review of RCTs	11 RCTs identified, with four completed studies included in the analysis	Evidence ranged from low to very low certainty, preventing firm conclusions about efficacy.
Aran et al., Molecular Autism	2021	Randomised placebo-controlled trial	150	Whole-plant extract improved some measures but not others. The researchers described evidence of efficacy as “mixed and insufficient”.
Bilge and Ekici, Journal of Cannabis Research	2021	Observational study	33	Parents reported improvements in some behavioural, language, cognitive and social outcomes, but there was no placebo group.

Why are cannabinoids being studied for autism?

Part of the scientific interest centres on the endocannabinoid system (ECS), a signalling system involved in processes including mood, sleep, memory and stress responses.

Researchers have investigated whether differences in the ECS could play a role in neurodevelopmental conditions such as autism and ADHD. 

A study led by Michael Siani-Rose, first published online in 2021 and later appearing in Cannabis and Cannabinoid Research, examined metabolic biomarkers in autistic children receiving medical cannabis.

Researchers identified 65 potential cannabis-responsive biomarkers that changed following treatment, with levels shifting towards those seen in a typically developing comparison group.

However, biomarker changes do not demonstrate that cannabis improves autism-related symptoms. The researchers said larger studies were needed to investigate the findings. 

Singh said he suspected the ECS could play a role in the effects he had observed clinically.

“In my clinical experience, medicinal cannabis can be very useful for those struggling with these mental health conditions, I suspect by influencing the endocannabinoid system and in turn other physiological systems,” the consultant psychiatrist said.

“Evidence is nascent but growing, however there is encouraging data from high CBD formulations. This I hope is encouragement enough to develop larger scale studies and build the evidence base in an area where few effective interventions exist.”

What do patients and clinicians say?

Alongside clinical research, autistic patients have reported using cannabis to manage symptoms including anxiety and sensory difficulties.

Mental health activist John Junior previously described cannabis as a “lifesaver” when speaking to Cannabis Health about managing sensory sensitivity and anxiety.

Consultant psychiatrist and cannabis clinician Dr Tahzid Ahsan also shared his experience of treating an adult with autism and ADHD with Cannabis Health in 2023.

The patient had struggled with concentration, anxiety and becoming overwhelmed in social and family situations. After beginning medical cannabis treatment, he reported improvements in his focus, concentration and interactions with others.

At his three-month review, Ahsan wrote: “He reported for the first time in his life he felt ‘he could understand others’.”

However, Ahsan also acknowledged the limitations of the wider evidence, writing: “Yes, we need more compelling, good-quality research around the safety and effectiveness of medical cannabis to understand more.”

Can you get medical cannabis for autism in the UK?

Cannabis-based medicines have been legally available on prescription in the UK since November 2018, but no product is licensed specifically for autism.

An autism diagnosis therefore does not automatically make someone eligible for medical cannabis. However, a specialist doctor can prescribe an unlicensed cannabis-based medicine where they consider it clinically appropriate for an individual patient.

The decision takes into account the symptoms or coexisting conditions being treated, previous treatments, other medications and potential risks.

NHS access remains highly restricted, with most UK medical cannabis patients accessing treatment privately.

Autism also frequently overlaps with other neurodevelopmental and mental-health conditions. ADHD is more common among autistic people, while anxiety and depression can also co-occur.

Cannabis Health has explored the separate evidence base around medical cannabis for ADHD in the UK.

What should parents know?

Some of the largest studies of cannabinoids and autism have involved children and young people. But this does not mean medical cannabis has been established as a safe or effective treatment for autistic children. 

In the 2021 Aran et al. trial published in Molecular Autism, no treatment-related serious adverse events were reported. However, sleepiness occurred in 28% of participants receiving the whole-plant extract compared with 8% receiving placebo, while decreased appetite was also more common among those receiving cannabinoids.

Long-term safety remains a gap in the evidence. The 2026 systematic review by Vasconcelos and colleagues found that reported adverse events were generally mild and non-serious, but concluded that larger trials were still needed to establish long-term safety.

“Medical cannabis” also does not describe a single treatment. Studies have investigated different formulations, including CBD-dominant extracts and products containing both CBD and THC.

CBD does not produce the intoxicating effects associated with THC, but it is not risk-free. Cannabinoids can cause side effects and interact with other medicines, while findings from one formulation or dose cannot automatically be applied to another.

What research is still needed?

Existing research provides some signals that cannabinoids may affect particular symptoms and behaviours experienced by autistic people, but there is not yet enough high-quality evidence to establish who may benefit, which formulations or doses are most appropriate, or their long-term safety.

Larger randomised controlled trials are needed to distinguish treatment effects from placebo effects and other factors, as well as to examine longer-term outcomes.

These questions will be among those explored at the Cannabis Health Symposium in London on 26 November.

The Medical cannabis and neurodiversity: exploring evidence and experience panel, scheduled for 2.20pm, will examine cannabis-based medicines in autism and ADHD, including gaps in conventional treatment, the role of the endocannabinoid system and the experiences of neurodivergent patients.

Frequently asked questions

Can medical cannabis treat autism?

There is not currently enough high-quality evidence to establish medical cannabis as an effective treatment for autism. Research has mainly examined its potential effects on particular symptoms, behaviours and coexisting conditions.

Can an autistic person get medical cannabis in the UK?

Potentially. No cannabis-based medicine is licensed specifically for autism, but specialist doctors can prescribe unlicensed cannabis-based medicines where they consider this clinically appropriate.

Can my autistic child be prescribed medical cannabis?

Cannabis-based medicines can be prescribed to children in limited circumstances, but prescribing is highly specialist and requires an individual assessment of the potential benefits and risks.

Is CBD the same as medical cannabis?

No. CBD is one of the cannabinoids found in cannabis. Prescribed cannabis-based medicines can contain different concentrations and combinations of CBD, THC and other compounds.

Is CBD safer than THC?

CBD does not produce the intoxicating effects associated with THC, but it is not risk-free. It can cause side effects and interact with other medicines, meaning the safety of any treatment needs to be considered individually.